Invivo Therapeutics Holdings (NVIV) 8.81 $NVIV Commit To

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Invivo Therapeutics Holdings (NVIV) 8.81 $NVIV

Commit To Purchase InVivo Therapeutics Holdings Corp At $7.50, Earn 34.8% Annualized Using Options
StockOptionsChannel.com - Fri Oct 09, 10:48AM CDT
Investors eyeing a purchase of InVivo Therapeutics Holdings Corp shares, but tentative about paying the going market price of $8.63/share, might benefit from considering selling puts among the alternative strategies at their disposal. One...
NVIV: 8.81 (+0.47)

5 Stocks Under $10 Set to Soar
at The Street - Thu Oct 08, 11:13AM CDT
These stocks trading for less than $10 a share are within range of triggering breakout trades.
ONE: 2.30 (+0.07), VTL: 4.57 (-0.05), ALIM: 2.61 (+0.04), LOOK: 0.63 (-0.01), NVIV: 8.81 (+0.47), ESI: 3.80 (+0.01), NPTN: 7.17 (-0.04), DXM: 0.19 (unch)

InVivo Therapeutics to Present at the 2015 Aegis Growth Conference
Business Wire - Mon Oct 05, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Mark Perrin, Chief Executive Officer and Chairman, is scheduled to present at the 2015 Aegis Growth Conference to be held October 7-9, 2015 in Las Vegas, Nevada. The company's presentation will be on Friday, October 9 at 10:45 AM PDT.
NVIV: 8.81 (+0.47)

InVivo Therapeutics Featured in Bloomberg Businessweek Article
Business Wire - Fri Oct 02, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the company was featured in a Bloomberg Businessweek article on Thursday, October 1.
NVIV: 8.81 (+0.47)

InVivo Therapeutics to Present at the Stem Cell Meeting on the Mesa
Business Wire - Tue Sep 29, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) announced today that Thomas Ulich, M.D., Chief Scientific Officer, will present at the annual Partnering Forum, part of the Stem Cell Meeting on the Mesa to be held October 7-9 at the Estancia La Jolla Hotel in La Jolla, CA. The company's presentation will be on Wednesday, October 7 at 11:00 AM (PDT). A live webcast will be available at http://stemcellmeetingonthemesa.com/webcast/.
NVIV: 8.81 (+0.47)

InVivo Therapeutics' CEO and Chairman, Mark Perrin, Featured in MedGadget Article
Business Wire - Mon Sep 28, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Mark Perrin, Chief Executive Officer and Chairman of the Board, was featured in a MedGadget article on Friday, September 25.
NVIV: 8.81 (+0.47)

InVivo Therapeutics to Present and Exhibit at the 65th CNS Annual Meeting
Business Wire - Mon Sep 21, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the company will be giving a poster presentation and exhibiting at the 65th Congress of Neurological Surgeons (CNS) Annual Meeting, to be held in New Orleans, LA, September 26-30, 2015. The e-poster, titled "Novel Surgical Procedure to Implant an Investigational Neuro-Spinal Scaffold Following Myelotomy for Treatment of Acute Traumatic Spinal Cord Injury: A Safety and Feasibility Study," is co-authored by Lorianne Masuoka, M.D., Kristin Neff, M.S., Thomas Ulich, M.D., and Alex Aimetti, Ph.D. InVivo will also host a networking event at this meeting aimed at engaging and connecting with current and potential Principal Investigators in our clinical study. At this event, Dr. Nicholas Theodore from Barrow Neurological Institute, who performed the first implantation of the Neuro-Spinal Scaffold in a human patient, will be discussing his case experience and narrating his surgical video as a way to inform the neurosurgical community about our novel therapeutic approach.
NVIV: 8.81 (+0.47)

InVivo Therapeutics' CEO and Chairman, Mark Perrin, Featured on DeviceTalks by MassDevice
Business Wire - Wed Sep 16, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Mark Perrin, Chief Executive Officer and Chairman of the Board, was featured on DeviceTalks, a MassDevice.com podcast, on Tuesday, September 15.
NVIV: 8.81 (+0.47)

InVivo Therapeutics Featured as an Industry Innovator by MassBio
Business Wire - Thu Sep 10, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the company has been featured in MassBio HQ's new series titled "Industry Innovators," which highlights Massachusetts Biotechnology Council (MassBio) members making an impact on the life sciences industry.
NVIV: 8.81 (+0.47)

InVivo Therapeutics Announces Mount Sinai Hospital in New York City as New Site for Neuro-Spinal Scaffold(TM) Clinical Trial
Business Wire - Wed Sep 09, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that The Mount Sinai Hospital in New York has been added as a clinical site in the company's ongoing clinical study of its investigational Neuro-Spinal Scaffold in patients with acute spinal cord injury (SCI). The Mount Sinai Hospital is acclaimed internationally for excellence in clinical care and is one of seven hospital campuses that make up the Mount Sinai Health System.
NVIV: 8.81 (+0.47)

InVivo Therapeutics Announces Enrollment of Fifth Patient in Pilot Spinal Cord Injury Study
Business Wire - Tue Sep 08, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the fifth patient has been enrolled in the company's ongoing pilot study of its investigational Neuro-Spinal Scaffold(TM) implant in patients with acute thoracic spinal cord injury at the Keck Hospital of University of Southern California (USC) in Los Angeles.
NVIV: 8.81 (+0.47)

InVivo Therapeutics to Present at Rodman & Renshaw 17th Annual Global Investment Conference
Business Wire - Tue Sep 01, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Mark Perrin, Chief Executive Officer and Chairman, is scheduled to present at the Rodman & Renshaw 17th Annual Global Investment Conference to be held September 8-10, 2015 at the St. Regis Hotel in New York City, NY. The company's presentation will be Thursday, September 10 at 1:45 PM (EDT). A live webcast will be available at http://wsw.com/webcast/rrshq25/nviv.
NVIV: 8.81 (+0.47)

InVivo Therapeutics to Present at the 17th Annual Spinal Research Network Meeting
Business Wire - Tue Aug 25, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Alex Aimetti, Ph.D., Senior Director, Medical Education and Scientific Support, will be giving a poster presentation at the 17th Annual Spinal Research Network Meeting to be held September 4-5, 2015 in London, UK. The abstract, titled "Benefits of Surgical Implantation of an Investigational Biodegradable Neuro-Spinal Scaffold in Various Animal Models of Acute Spinal Cord Contusion Injury: Clinical Translation," is co-authored by Dr. Aimetti, James Guest, M.D., Nicholas Theodore, M.D., Domagoj Coric, M.D., Lorianne Masuoka, M.D., Simon Moore, Ph.D., Richard Layer, Ph.D., and Thomas Ulich, M.D.
NVIV: 8.81 (+0.47)

InVivo Therapeutics Announces Listing Transfer to Nasdaq Global Market
Business Wire - Mon Aug 24, 8:35AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the listing of the company's common stock has been transferred to the Nasdaq Global Market. The company's common stock previously traded on the Nasdaq Capital Market and will continue to trade under the same symbol NVIV. This follows the July 29th announcement by InVivo that the company has been added to the Russell Global, Russell 3000(R), Russell 2000(R), and Russell Microcap indexes.
NVIV: 8.81 (+0.47)

InVivo Therapeutics Featured in Front Page Article in The Boston Globe
Business Wire - Mon Aug 24, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) has announced that the company and the company's ongoing trial of its investigational Neuro-Spinal Scaffold in patients with acute thoracic spinal cord injury were featured in a front page article in The Boston Globe on Sunday, August 23. The article was published on the front page of The Boston Globe's website (www.bostonglobe.com) on Friday, August 21. The story was produced by Stat, a new national publication from Boston Globe Media Partners that will launch this fall with coverage of health, medicine, and life sciences. The Boston Globe reaches over 4 million people per month between its online and print content.
NVIV: 8.81 (+0.47)

InVivo Therapeutics Announces Enrollment of Fourth Patient in Pilot Spinal Cord Injury Trial
Business Wire - Thu Aug 20, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that a fourth patient has been enrolled in the company's ongoing pilot trial of its investigational Neuro-Spinal Scaffold in patients with acute thoracic spinal cord injury at the UC Davis Medical Center in Sacramento, CA.
NVIV: 8.81 (+0.47)

InVivo Therapeutics' CEO and Chairman, Mark Perrin, Interviewed by Maria Bartiromo on FOX Business Network's "Mornings with Maria"
Business Wire - Thu Aug 13, 10:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Mark Perrin, Chief Executive Officer and Chairman of the Board, appeared on the Fox Business Network program "Mornings with Maria" on Thursday, August 13. The program, anchored by FOX Business Global Markets Editor Maria Bartiromo, runs weekdays from 6-9 A.M. (ET) and reaches an estimated 5.3 million viewers. The groundbreaking financial journalist covers the day's top business news and interviews leaders of some of the world's largest companies.
NVIV: 8.81 (+0.47)

InVivo Therapeutics Announces New Jersey's Cooper Neurological Institute as New Clinical Site for Neuro-Spinal Scaffold
Business Wire - Wed Aug 12, 3:30PM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the Cooper Neurological Institute (CNI) in Camden, NJ has been added as a clinical site in the company's ongoing pilot study of its investigational Neuro-Spinal Scaffold in patients with acute spinal cord injury (SCI). CNI is a part of Cooper University Health Care, a network providing care to Southern New Jersey and the entire Delaware Valley. Steven Yocom, DO, Assistant Professor of Neurosurgery and Co-Director of the CNI Spine Program, has been named Principal Investigator at this site.
NVIV: 8.81 (+0.47)

InVivo Therapeutics Announces Promotions and New Organizational Roles to Further Drive Market Development and Awareness of Spinal Cord Injury Innovation
Business Wire - Thu Aug 06, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced promotions for two members of its management team.
RGEN: 25.28 (+0.76), NVIV: 8.81 (+0.47)

InVivo Therapeutics Reports 2015 Second Quarter Financial Results and Business Update
Business Wire - Wed Aug 05, 4:00PM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today reported financial results for the quarter ended June 30, 2015.
NVIV: 8.81 (+0.47)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 125

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading
Fluence Energy Faces Heat: Class Action Lawsuit Unfolds

Updated Category News Views 41

Fluence Energy's Difficult Waters Investors in Fluence Energy (NASDAQ: FLNC) are having a moment of reckoning, no doubt. November 2nd saw a nearly 9% drop in FLNC stock, further fueled by the sudden departures of the CEO and CFO just days earlier. This marks a bitter chapter for Fluence as its stock continues to bleed, leaving many wondering what seismic shifts are yet to...

Continue Reading
LinkedIn Shines: Brands Face Social Media Slump

Updated Category News Views 35

LinkedIn: The Unsung Hero in Social Platforms In a world where social media seems to be as unpredictable as the stock market, LinkedIn is surprisingly holding the line. According to Vista Social's 2027 report, LinkedIn proudly boasts the highest median engagement rate among brand pages at 5.8%. Now, in the wild west of social media, where reach is getting tougher to snag,...

Continue Reading
FDA Changes Shake Up Medtech Inspections Landscape

Updated Category News Views 92

Inspecting the Changing FDA Landscape If you’ve been treating FDA inspections like a ride down memory lane, it's time for a wake-up call. What F. David Rothkopf plans to tell the medical device teams at the MEDevice Silicon Valley event is simple: the game has changed. The FDA’s Quality Management System Regulation (QMSR) that kicked in on February 2, 2026, isn’t...

Continue Reading
ICEYE Launches Gen5 SAR Satellite for Unrivaled Clarity

Updated Category News Views 60

Well, if you've been sleeping under a rock and missed the news, ICEYE just dropped another bombshell in the satellite biz. Gen5 is the name of the game, and it's claiming the spotlight for its razor-sharp imaging prowess. Now, we're talking about a satellite that supposedly snaps pictures with a resolution as fine as 11 cm. That's like spotting a flea on a dog's back from...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 279

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 201

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Neil deGrasse Tyson Headlines HIMSS27 with Cosmic Insights

Updated Category News Views 114

celebrated science communicator, is set to close out the HIMSS27 conference with a keynote that's bound to leave a lasting impression. It's a fitting intersection of stars and stethoscopes, as the astrophysicist brings his expansive lens to the nitty-gritty of healthcare innovation. Splicing Science with Storytelling Folks, this ain't your standard healthcare gathering....

Continue Reading
Ampace Focuses on Battery Safety Standards at RE+ 2026

Updated Category News Views 146

Battery Safety Takes Center Stage No mystery here: the safety of our beloved lithium-ion batteries is crucial, especially as AI data centers sprout like weeds. At RE+ 2026, Ampace is putting its chips on the table by spotlighting this hot topic. Dr. Drew Feng, their Chief Safety Officer, is set to reveal the big guns: findings from the PU100 large-scale fire test. Mark...

Continue Reading
Waterfall Backs $48M Loan for Disney-area Hotel Upgrade

Updated Category News Views 175

A $48 Million Shot in the Arm for Portofino Inn Old-school Anaheim just got a real estate shake-up. Waterfall Asset Management's decision to lend a hefty $48 million to Dynamic City Capital (DCC) is more than just a financial move—it's a bet on tourism's bedrock, Disneyland. They're sinking this cash into the Portofino Inn & Suites, located a stone's throw from the...

Continue Reading

Top 5 Most Recently Viewed Articles

Sunrise New Energy Unveils Innovative Solid-State Battery Patent

Updated Category News Views 205

Sunrise New Energy's Patent for Solid-State Battery Innovation Sunrise New Energy Co., Ltd. (NASDAQ: EPOW) has made significant strides in energy technology with the announcement of a groundbreaking invention patent for a novel method of creating lithium cerate-coated graphite iron oxide anode material. This development is a significant leap forward in the realm of...

Continue Reading
Leadership Transition at Lykos Therapeutics Following FDA Setback

Updated Category News Views 103

Leadership Change at Lykos Therapeutics After FDA Setback Amy Emerson has resigned as CEO of Lykos Therapeutics following significant regulatory hurdles. This change comes after the Food and Drug Administration (FDA) recently rejected the company's application for its ecstasy-based therapy aimed at treating post-traumatic stress disorder (PTSD). Consequences of FDA...

Continue Reading
RADCOM to Showcase Innovations at Upcoming Growth Conference

Updated Category News Views 228

RADCOM to Showcase Innovations at Growth Conference RADCOM Ltd. (Nasdaq: RDCM) is gearing up for a prominent appearance at the 28th Annual Needham Growth Conference. The conference will take place at the esteemed Lotte NY Palace Hotel, where the company is excited to highlight its cutting-edge technological advancements. Leadership Team Participation At this significant...

Continue Reading
Shoppers Prioritize Savings Over Convenience, Survey Reveals

Updated Category News Views 81

New Insights into Consumer Preferences During Holidays A recent survey conducted by GoDaddy sheds light on the evolving preferences of consumers as the holiday season approaches. The findings reveal that convenience often takes a backseat to cost savings, which fundamentally impacts how businesses engage with their customers. The Importance of Cost Savings According to...

Continue Reading
Criteo's Insider Trading Insights: What You Need to Know

Updated Category News Views 116

Understanding Recent Insider Trading at Criteo Recently, significant insider trading activity has caught the attention of investors and analysts. Notably, Ryan Damon, Chief Legal Officer at Criteo, made headlines with a prominent stock sale involving his holdings in the company. Insider Sales: A Breakdown During a recent filing, it was disclosed that Ryan Damon sold 3,393...

Continue Reading